Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032

Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route Of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032



The global bronchodilators market size is expected to reach USD 30.88 billion by 2032, according to a new study by Polaris Market Research. The report “Bronchodilators Market Share, Size, Trends, Industry Analysis Report, By Disease (Asthma, COPD and Others); By Route of Administration; By Drug Class; By Mode of Action; By Region; Segment Forecast, 2023 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing preference of clinicians and respiratory experts on utilizing novel bronchodilator combinations such as short-acting beta 2 agonists along with corticosteroids for immediate relief along with key industry players commercializing these drugs to cater the rising demand is estimated to surge availability and adoption of bronchodilators. This coupled with rise in ageing population globally at a higher risk of developing Lower Respiratory Tract Infections (LRTI) are anticipated to augment the growth of the market.

For instance, in January 2023, the U.S. Food and Drug administration approved Airsupra for the therapy of Asthma with exacerbations. The innovative pressurized metering platform delivers the combination albuterol/budesonide as a rescue therapy, supplemented by maintenance of additional albuterol dose. The increasing need of quick acting bronchodilators is promoting key players in gaining approvals for various combinations to cater major respiratory disorders thereby supporting the growth of the market.

Recent studies in respiratory medicine have shown increasing occurrence of bronchoconstriction cases in children which is growing rapidly among the patient pool. Various factors such as genetics, unhealthy food habits, among others are making of pediatrics susceptible to long term respiratory conditions such as Asthma. This along with awareness campaigns and clinical research by various healthcare bodies around the globe, promoting pediatric respiratory medication is estimated to support the growth of the market.

For instance, a research study published by the NCBI, in August 2022, the prevalence of children suffering from Asthma in the U.S. was estimated to be 8.4%, estimated over 6 million patient population. Moreover, 66.0% of children were found to be suffering from severe cases of Asthma with a high morbidity rate. Therefore, the increasing presence of pediatric patients along with the existing patient pool is anticipated to drive the demand for bronchodilators owing to maintenance therapy and bronchial alleviation in cases of severity.

The impact of Covid-19 on the bronchodilator market was favorable due facilitation of normal breathing for patients affected by the corona virus induced respiratory emergencies. Moreover, high incidence rates of life threatening diseases such as pneumonia during the period demanded an inflow of respiratory medications and supportive therapies such as bronchodilation. This coupled with deployment of emergency protocols and healthcare guidelines, increasing hospital admissions with respiratory complaints promoted the use of bronchodilators thereby bolstering the growth of the market during the pandemic.

Bronchodilators Market Report Highlights

COPD segment is anticipated to grow at a high CAGR over the forecast period owing to rising awareness of bronchodilation therapy benefits in respiratory medicine along with high prevalence of COPD among patient population.

Oral accounted for largest revenue share which is accelerated by the higher success rates of oral drugs in reducing bronconstriction episodes along increasing applications of Xanthine derivatives in supportive therapies.

Beta-Adrenergics is expected to hold the significant market share over the forecast period due to its conventional wisdom in respiratory medicine along with effective treatment profile as compared to other classes of bronchodilators.

North America is expected to grow prominently over the projected period owing to increasing incidence of bronchitis and other respiratory disorders triggered due to air pollution.

The global players in the market include GSK, AstraZeneca, Teva Pharmaceutical, Cipla Inc., Mylan, Merck, Novartis, Boehringer Ingelheim, Sun Pharmaceutical, Glenmark Pharmaceuticals.

Polaris Market Research has segmented the bronchodilators market report based by disease, by route of administration, by drug class, by mode of action and region:

Bronchodilators, Disease Outlook (Revenue - USD Billion, 2019 - 2032)

Asthma

COPD

Others

Bronchodilators, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

Inhalable

Oral

Injection

Bronchodilators, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

Beta-Adrenergics

Anticholinergics

Xanthine Derivatives

Phosphodiesterase Inhibitors

Combination Drugs

Bronchodilators, Mode of Action Outlook (Revenue - USD Billion, 2019 - 2032)

Short Acting

Long Acting

Bronchodilators, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa


1. Introduction
1.1. Report Description
1.1.1. Objectives of the Study
1.1.2. Market Scope
1.1.3. Assumptions
1.2. Stakeholders
2. Executive Summary
2.1. Market Highlights
3. Research Methodology
3.1. Overview
3.1.1. Data Mining
3.2. Data Sources
3.2.1. Primary Sources
3.2.2. Secondary Sources
4. Global Bronchodilators Market Insights
4.1. Bronchodilators – Industry Snapshot
4.2. Bronchodilators Market Dynamics
4.2.1. Drivers and Opportunities
4.2.1.1. Rise in incidence of asthma and COPD
4.2.1.2. Various growth opportunities in emerging economies
4.2.2. Restraints and Challenges
4.2.2.1. Side effects associated with bronchodilators
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers (Moderate)
4.3.2. Threats of New Entrants: (Low)
4.3.3. Bargaining Power of Buyers (Moderate)
4.3.4. Threat of Substitute (Moderate)
4.3.5. Rivalry among existing firms (High)
4.4. PESTLE Analysis
4.5. Bronchodilators Industry Trends
4.6. Value Chain Analysis
4.7. COVID-19 Impact Analysis
5. Global Bronchodilators Market, by Disease
5.1. Key Findings
5.2. Introduction
5.2.1. Global Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
5.3. Asthma
5.3.1. Global Bronchodilators Market, by Asthma, by Region, 2019-2032 (USD Billion)
5.4. COPD
5.4.1. Global Bronchodilators Market, by COPD, by Region, 2019-2032 (USD Billion)
5.5. Others
5.5.1. Global Bronchodilators Market, by Others, by Region, 2019-2032 (USD Billion)
6. Global Bronchodilators Market, by Route Of Administration
6.1. Key Findings
6.2. Introduction
6.2.1. Global Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
6.3. Inhalable
6.3.1. Global Bronchodilators Market, by Inhalable, by Region, 2019-2032 (USD Billion)
6.4. Oral
6.4.1. Global Bronchodilators Market, by Oral, by Region, 2019-2032 (USD Billion)
6.5. Injection
6.5.1. Global Bronchodilators Market, by Injection, by Region, 2019-2032 (USD Billion)
7. Global Bronchodilators Market, by Drug Class
7.1. Key Findings
7.2. Introduction
7.2.1. Global Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
7.3. Beta-Adrenergics
7.3.1. Global Bronchodilators Market, by Beta-Adrenergics, by Region, 2019-2032 (USD Billion)
7.4. Anticholinergics
7.4.1. Global Bronchodilators Market, by Anticholinergics, by Region, 2019-2032 (USD Billion)
7.5. Xanthine Derivatives
7.5.1. Global Bronchodilators Market, by Xanthine Derivatives, by Region, 2019-2032 (USD Billion)
7.6. Phosphodiesterase Inhibitors
7.6.1. Global Bronchodilators Market, by Phosphodiesterase Inhibitors, by Region, 2019-2032 (USD Billion)
7.7. Combination Drugs
7.7.1. Global Bronchodilators Market, by Combination Drugs, by Region, 2019-2032 (USD Billion)
8. Global Bronchodilators Market, by Mode of Action
8.1. Key Findings
8.2. Introduction
8.2.1. Global Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
8.3. Short Acting
8.3.1. Global Bronchodilators Market, by Short Acting, by Region, 2019-2032 (USD Billion)
8.4. Long Acting
8.4.1. Global Bronchodilators Market, by Long Acting, by Region, 2019-2032 (USD Billion)
9. Global Bronchodilators Market, by Geography
9.1. Key findings
9.2. Introduction
9.2.1. Bronchodilators Market Assessment, By Geography, 2019-2032 (USD Billion)
9.3. Bronchodilators Market – North America
9.3.1. North America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.3.2. North America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.3.3. North America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.3.4. North America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.3.5. Bronchodilators Market – U.S.
9.3.5.1. U.S.: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.3.5.2. U.S.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.3.5.3. U.S.: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.3.5.4. U.S.: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.3.6. Bronchodilators Market – Canada
9.3.6.1. Canada: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.3.6.2. Canada: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.3.6.3. Canada: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.3.6.4. Canada: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4. Bronchodilators Market – Europe
9.4.1. Europe: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.2. Europe: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.3. Europe: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.4. Europe: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.5. Bronchodilators Market – UK
9.4.5.1. UK: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.5.2. UK: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.5.3. UK: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.5.4. UK: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.6. Bronchodilators Market – France
9.4.6.1. France: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.6.2. France: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.6.3. France: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.6.4. France: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.7. Bronchodilators Market – Germany
9.4.7.1. Germany: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.7.2. Germany: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.7.3. Germany: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.7.4. Germany: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.8. Bronchodilators Market – Italy
9.4.8.1. Italy: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.8.2. Italy: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.8.3. Italy: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.8.4. Italy: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.9. Bronchodilators Market – Spain
9.4.9.1. Spain: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.9.2. Spain: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.9.3. Spain: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.9.4. Spain: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.10. Bronchodilators Market – Netherlands
9.4.10.1. Netherlands: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.10.2. Netherlands: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.10.3. Netherlands: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.10.4. Netherlands: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.4.11. Bronchodilators Market – Russia
9.4.11.1. Russia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.4.11.2. Russia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.4.11.3. Russia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.4.11.4. Russia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5. Bronchodilators Market – Asia Pacific
9.5.1. Asia Pacific: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.2. Asia Pacific: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.3. Asia Pacific: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.4. Asia Pacific: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.5. Bronchodilators Market – China
9.5.5.1. China: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.5.2. China.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.5.3. China: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.5.4. China: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.6. Bronchodilators Market – India
9.5.6.1. India: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.6.2. India.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.6.3. India: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.6.4. India: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.7. Bronchodilators Market – Japan
9.5.7.1. Japan: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.7.2. Japan.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.7.3. Japan: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.7.4. Japan: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.8. Bronchodilators Market – Malaysia
9.5.8.1. Malaysia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.8.2. Malaysia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.8.3. Malaysia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.8.4. Malaysia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.9. Bronchodilators Market – Indonesia
9.5.9.1. Indonesia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.9.2. Indonesia.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.9.3. Indonesia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.9.4. Indonesia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.5.10. Bronchodilators Market – South Korea
9.5.10.1. South Korea: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.5.10.2. South Korea.: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.5.10.3. South Korea: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.5.10.4. South Korea: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6. Bronchodilators Market – Middle East & Africa
9.6.1. Middle East & Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.6.2. Middle East & Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.6.3. Middle East & Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.6.4. Middle East & Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6.5. Bronchodilators Market – Saudi Arabia
9.6.5.1. Saudi Arabia: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.6.5.2. Saudi Arabia: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.6.5.3. Saudi Arabia: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.6.5.4. Saudi Arabia: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6.6. Bronchodilators Market – South Africa
9.6.6.1. South Africa: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.6.6.2. South Africa: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.6.6.3. South Africa: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.6.6.4. South Africa: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6.7. Bronchodilators Market – Israel
9.6.7.1. Israel: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.6.7.2. Israel: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.6.7.3. Israel: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.6.7.4. Israel: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.6.8. Bronchodilators Market – UAE
9.6.8.1. UAE: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.6.8.2. UAE: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.6.8.3. UAE: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.6.8.4. UAE: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.7. Bronchodilators Market – Latin America
9.7.1. Latin America: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.7.2. Latin America: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.7.3. Latin America: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.7.4. Latin America: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.7.5. Bronchodilators Market – Mexico
9.7.5.1. Mexico: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.7.5.2. Mexico: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.7.5.3. Mexico: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.7.5.4. Mexico: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.7.6. Bronchodilators Market – Brazil
9.7.6.1. Brazil: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.7.6.2. Brazil: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.7.6.3. Brazil: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.7.6.4. Brazil: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
9.7.7. Bronchodilators Market – Argentina
9.7.7.1. Argentina: Bronchodilators Market, by Disease, 2019-2032 (USD Billion)
9.7.7.2. Argentina: Bronchodilators Market, by Mode of Action, 2019-2032 (USD Billion)
9.7.7.3. Argentina: Bronchodilators Market, by Route Of Administration, 2019-2032 (USD Billion)
9.7.7.4. Argentina: Bronchodilators Market, by Drug Class, 2019-2032 (USD Billion)
10. Competitive Landscape
10.1. Expansion and Acquisition Analysis
10.1.1. Expansion
10.1.2. Acquisitions
10.2. Partnerships/Collaborations/Agreements/Exhibitions
11. Company Profiles
11.1. GSK
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Benchmarking
11.1.4. Recent Development
11.2. AstraZeneca
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Benchmarking
11.2.4. Recent Development
11.3. Teva Pharmaceutical
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Benchmarking
11.3.4. Recent Development
11.4. Cipla Inc
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Benchmarking
11.4.4. Recent Development
11.5. Mylan
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Benchmarking
11.5.4. Recent Development
11.6. Merck
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Benchmarking
11.6.4. Recent Development
11.7. Novartis
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Benchmarking
11.7.4. Recent Development
11.8. Boehringer Ingelheim
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Benchmarking
11.8.4. Recent Development
11.9. Sun Pharmaceutical Industries
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Benchmarking
11.9.4. Recent Development
11.10. Glenmark Pharmaceuticals Limited
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Benchmarking
11.10.4. Recent Development

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings